Editas Medicine (EDIT)

Editas builds its platform around CRISPR-associated enzymes, including Cas9 and Cas12a, together with guide RNAs and delivery methods designed for specific therapeutic applications. This technology can be applied in different ways, including editing cells outside the body before returning them to a patient, or potentially editing cells directly inside the body. The company’s programs have focused on serious genetic diseases where a precise DNA edit may offer meaningful clinical benefit.

One of Editas’ most closely watched areas is its work in hematology, including gene-editing approaches for inherited blood disorders such as sickle cell disease and beta thalassemia. These conditions are caused by genetic mutations that affect hemoglobin, making them natural targets for genomic medicine. Like other clinical-stage biotech companies, Editas has not built its investment case on current product sales, but on the progress of its research pipeline, trial data, regulatory interactions and partnerships.

EDIT gives public-market investors exposure to the CRISPR therapeutics field, which is scientifically promising but carries significant development risk. The company’s value is closely linked to whether its editing platform can demonstrate safety, durable efficacy and manufacturability in human studies, and whether it can compete with other gene therapy and gene-editing developers.